Cantor Fitzgerald Comments on Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Ardelyx in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will post earnings per share of ($0.13) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Several other analysts also recently commented on the company. Piper Sandler upped their price objective on Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Raymond James restated a “strong-buy” rating and set a $13.00 price target (down previously from $15.00) on shares of Ardelyx in a research note on Friday, February 21st. HC Wainwright reiterated a “neutral” rating and issued a $5.50 price objective on shares of Ardelyx in a research report on Friday, February 21st. BTIG Research began coverage on shares of Ardelyx in a research note on Tuesday. They issued a “buy” rating and a $14.00 price objective on the stock. Finally, Jefferies Financial Group reduced their target price on shares of Ardelyx from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, January 2nd. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.44.

Ardelyx Trading Up 0.6 %

ARDX opened at $5.44 on Thursday. Ardelyx has a 52 week low of $4.32 and a 52 week high of $9.79. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -34.00 and a beta of 0.85. The business’s 50 day moving average is $5.37 and its two-hundred day moving average is $5.60. The company has a quick ratio of 4.31, a current ratio of 4.58 and a debt-to-equity ratio of 0.87.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The company had revenue of $116.13 million for the quarter, compared to the consensus estimate of $111.16 million. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%.

Insider Activity at Ardelyx

In other Ardelyx news, Director David M. Mott purchased 213,300 shares of Ardelyx stock in a transaction on Thursday, December 19th. The shares were bought at an average price of $4.67 per share, with a total value of $996,111.00. Following the purchase, the director now directly owns 1,638,765 shares in the company, valued at $7,653,032.55. This trade represents a 14.96 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael Raab sold 22,964 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $5.62, for a total transaction of $129,057.68. Following the transaction, the chief executive officer now directly owns 1,085,755 shares of the company’s stock, valued at approximately $6,101,943.10. This represents a 2.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 490,029 shares of company stock valued at $2,377,766 and have sold 141,408 shares valued at $761,963. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARDX. Ensign Peak Advisors Inc increased its holdings in Ardelyx by 3.1% during the 4th quarter. Ensign Peak Advisors Inc now owns 73,950 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 2,200 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in Ardelyx by 3.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 90,000 shares of the biopharmaceutical company’s stock valued at $599,000 after acquiring an additional 3,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Ardelyx by 2.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 154,625 shares of the biopharmaceutical company’s stock worth $788,000 after acquiring an additional 3,550 shares in the last quarter. Swiss National Bank increased its position in shares of Ardelyx by 1.0% in the 4th quarter. Swiss National Bank now owns 463,100 shares of the biopharmaceutical company’s stock worth $2,348,000 after purchasing an additional 4,800 shares during the last quarter. Finally, Orion Portfolio Solutions LLC raised its stake in shares of Ardelyx by 42.7% in the 4th quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 4,933 shares in the last quarter. Hedge funds and other institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.